Topics

Biogen acquires Pfizer Alzheimer's drug in $75M deal

05:09 EST 15 Jan 2020 | SmartBrief

Pfizer's experimental Alzheimer's disease drug candidate PF-05251749, which interacts with the portion of the brain regulatin -More

Original Article: Biogen acquires Pfizer Alzheimer's drug in $75M deal

NEXT ARTICLE

More From BioPortfolio on "Biogen acquires Pfizer Alzheimer's drug in $75M deal"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...